MedGenome Launches OncoTrack MRD For Personalised Cancer Monitoring

In September 2026, MedGenome recently launched OncoTrack MRD, which is a personalized and ultrasensitive NGS-based tumor-informed Molecular Residual Disease (MRD) test for cancer patients. Launched in Bengaluru on September 3, the test uses a patient’s own tumor tissue to identify tumor-specific signals and then tracks circulating tumor DNA through blood samples. The company says the test can detect and measure residual cancer, identify potential recurrence earlier than conventional methods, and support treatment decisions. It can also be repeated through a blood test multiple times a year, as clinically appropriate.

OncoTrack MRD uses a patient’s own tumor tissue rather than relying on a generic set of mutations. The company says this allows it to track tumor-specific signals through circulating tumor DNA. It is also meant to complement, rather than replace, imaging and clinical assessment. That distinction matters because a molecular signal is not the same as a visible tumor. And a positive MRD result does not automatically mean the same treatment decision across all solid cancers. The evidence around MRD-guided treatment is still developing across different tumor types.

OncoTrack MRD can also be applied across a broad range of solid tumors, including breast, colorectal, lung, ovarian and other gynecological cancers, pancreatic, oesophageal, gastric, hepatocellular and thoracic cancers, as well as melanoma. The company particularly highlights resected Stage II/III colorectal cancer, early-stage non-small cell lung cancer (NSCLC), and early or locally advanced breast cancer after curative-intent treatment. The main aim is to add another layer to what doctors already know from scans and clinical assessment.

The company also said that the approach is supported by global clinical evidence, including studies from the CIRCULATE-Japan program and international oncology trials exploring the role of tumor-informed circulating tumor DNA in treatment monitoring and recurrence detection.

Impact on the Healthcare Market

Unlike other tests that are based on a generic panel of mutations, OncoTrack MRD uses tumour-specific signals identified from an individual patient's cancer tissue. This particular approach is designed to enable longitudinal monitoring through a repeatable blood test, which can be undertaken multiple times a year depending on clinical requirements. 
The test can support monitoring across a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, oesophageal, gastric and liver cancers, as well as melanoma, and is particularly suited for patients who have completed curative-intent treatment for selected early-stage or locally advanced cancers. With home sample collection and nationwide availability, OncoTrack MRD aims to expand access to longitudinal molecular monitoring across India, as precision oncology increasingly combines genomic insights with imaging and clinical evaluation.

Impact on the Oncology Clinical Trials Market

The global oncology clinical trials market was estimated at USD 13.60 billion in 2024 and is predicted to increase from USD 14.27 billion in 2025 to approximately USD 22.76 billion by 2034, expanding at a CAGR of 5.28% from 2025 to 2034.

According to Precedence Research, the increasing global incidence of cancer serves as a driving force behind the expansion of oncology clinical trials. With a growing number of individuals grappling with various types of cancer, the imperative to invest in research and development becomes more pronounced. The pursuit of novel and improved therapeutic approaches becomes paramount, making clinical trials indispensable in addressing the evolving challenges posed by diverse forms of cancer. The trend towards personalized medicine, tailoring treatments based on individual patient characteristics and genetic makeup, is fueling the growth of oncology clinical trials.

Advancements in technology, including enhanced diagnostic tools and advanced data analysis, are also playing a pivotal role in shaping the realm of oncology clinical trials. These progressions not only refine the precision of patient categorization and biomarker identification but also enable real-time monitoring of treatment responses. Consequently, these technological strides significantly elevate the effectiveness and efficiency of clinical research processes.

Impact on the Oncology Market

The global oncology market size was calculated at USD 250.88 billion in 2025 and is predicted to increase from USD 279.73 billion in 2026 to approximately USD 732.45 billion by 2035, expanding at a CAGR of 11.31% from 2026 to 2035.

According to Precedence Research, the increasing prevalence of cancer, growing awareness of early cancer detection, and advancements in diagnostic and therapeutic technologies drive the market. The oncology market is experiencing robust growth, driven by growing oncology concerns, the availability of point-of-care devices and personalized medicines, and increasing cancer research. Cancer research is supported by several government bodies through initiatives and funding programs.

The startup ecosystem is also maturing, driven by increasing venture capital investments and technological advancements. Oncology startups are now pioneering new frontiers in cancer treatment, early diagnostics, and precision medicine. Sustainability trends also place a high focus on balancing cutting-edge, life-extending cancer care with ecological responsibility, financial viability, and resource optimization. 

Expert Opinion

Vedam Ramprasad said the increasing cancer burden in India had created a need for more sensitive tools capable of identifying recurrence risk even when conventional assessments show no visible signs of disease. 
“Our personalized and ultrasensitive NGS-based tumor-informed MRD test adds an important layer of molecular insight to complement existing clinical assessment and imaging,” he said. “OncoTrack MRD reflects our continued commitment to Make in India for the world by making global quality advanced precision oncology affordable and accessible.”